Profile data is unavailable for this security.
About the company
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
- Revenue in USD (TTM)1.46bn
- Net income in USD92.09m
- Incorporated2014
- Employees2.48k
- LocationPhibro Animal Health Corp300 Frank W. Burr Blvd.Suite 21, 65 Challenger RoadTEANECK 07666United StatesUSA
- Phone+1 (201) 329-7300
- Fax+1 (302) 655-5049
- Websitehttps://www.pahc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 6.31m | -425.87m | 1.68bn | 143.00 | -- | 40.06 | -- | 265.83 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Innoviva Inc | 388.52m | 127.34m | 1.68bn | 127.00 | 17.39 | 1.66 | 10.02 | 4.32 | 1.29 | 1.29 | 4.57 | 13.51 | 0.292 | 1.98 | 4.21 | 3,059,221.00 | 9.57 | 20.06 | 10.66 | 22.10 | 81.50 | -- | 32.78 | 62.81 | 13.33 | 18.15 | 0.2031 | -- | 15.54 | 6.57 | -86.98 | -31.69 | 223.78 | -- |
| Vericel Corp | 258.72m | 13.08m | 1.72bn | 357.00 | 181.46 | 5.34 | 74.11 | 6.64 | 0.1872 | 0.1872 | 4.86 | 6.37 | 0.6133 | 4.00 | 4.75 | 724,697.50 | 3.10 | -1.03 | 3.46 | -1.18 | 73.81 | 69.10 | 5.06 | -1.61 | 4.47 | -- | 0.002 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| ANI Pharmaceuticals Inc | 826.88m | 34.14m | 1.72bn | 897.00 | 47.04 | 3.41 | 13.21 | 2.08 | 1.63 | 1.63 | 40.89 | 22.51 | 0.6135 | 2.18 | 3.68 | 921,828.30 | 3.01 | -2.99 | 3.63 | -3.49 | 61.14 | 58.84 | 4.91 | -6.12 | 2.04 | 3.83 | 0.5508 | -- | 26.20 | 24.36 | -230.19 | -- | 19.60 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.75bn | 382.00 | -- | 37.12 | 127.55 | 6.98 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| Sarepta Therapeutics Inc | 2.41bn | -271.51m | 1.82bn | 1.37k | -- | 1.38 | -- | 0.7554 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Organon & Co | 6.30bn | 501.00m | 1.84bn | 10.00k | 3.67 | 2.03 | 2.18 | 0.2913 | 1.92 | 1.92 | 24.20 | 3.48 | 0.4791 | 1.97 | 3.98 | 630,100.00 | 3.81 | 11.52 | 4.81 | 14.94 | 55.04 | 62.30 | 7.95 | 20.24 | 1.20 | 2.50 | 0.9069 | 16.02 | 2.24 | -3.81 | -15.54 | -23.54 | 30.71 | -- |
| Aurinia Pharmaceuticals Inc | 265.81m | 77.84m | 1.89bn | 300.00 | 25.51 | 5.16 | 19.39 | 7.10 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Ocular Therapeutix Inc | 51.95m | -265.94m | 1.97bn | 325.00 | -- | 2.99 | -- | 37.96 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
| Perrigo Company PLC | 4.28bn | -29.20m | 1.98bn | 8.38k | -- | 0.445 | 6.54 | 0.4622 | -0.2128 | -0.3764 | 31.00 | 32.31 | 0.4023 | 2.34 | 5.75 | 511,015.60 | -0.2743 | -0.7059 | -0.3124 | -0.8082 | 35.46 | 34.96 | -0.682 | -1.76 | 1.44 | 2.41 | 0.4505 | -- | -6.06 | 2.48 | -3,552.27 | -- | -16.23 | 18.65 |
| Harmony Biosciences Holdings Inc | 825.94m | 185.68m | 2.06bn | 246.00 | 11.29 | 2.47 | 9.85 | 2.50 | 3.18 | 3.18 | 14.13 | 14.50 | 0.7732 | 26.70 | 9.07 | -- | 17.38 | 15.64 | 21.20 | 19.13 | 77.70 | 79.78 | 22.48 | 20.61 | 3.72 | -- | 0.1679 | 0.00 | 22.80 | 160.18 | 12.91 | -- | -56.63 | -- |
| Phibro Animal Health Corp | 1.46bn | 92.09m | 2.08bn | 2.48k | 22.73 | 6.24 | 14.55 | 1.42 | 2.26 | 2.26 | 35.88 | 8.21 | 1.09 | 2.09 | 7.18 | 591,646.40 | 6.84 | 3.89 | 8.47 | 4.87 | 32.56 | 31.14 | 6.29 | 3.69 | 1.22 | 4.39 | 0.6875 | 52.02 | 27.37 | 10.12 | 1,897.68 | 7.54 | 2.38 | 0.00 |
| Ultragenyx Pharmaceutical Inc | 630.60m | -579.83m | 2.27bn | 1.29k | -- | 247.45 | -- | 3.60 | -5.94 | -5.94 | 6.46 | 0.095 | 0.4622 | 2.02 | 6.13 | 487,324.60 | -42.50 | -33.04 | -55.49 | -38.84 | 84.69 | 91.29 | -91.95 | -127.45 | 1.74 | -17.52 | 0.9809 | -- | 29.01 | 40.12 | 6.17 | -- | -4.24 | -- |
Data as of Feb 13 2026. Currency figures normalised to Phibro Animal Health Corp's reporting currency: US Dollar USD
42.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.92m | 14.28% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.37m | 6.69% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 894.04k | 4.37% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 785.82k | 3.84% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 555.20k | 2.72% |
| Geode Capital Management LLCas of 30 Sep 2025 | 547.16k | 2.68% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 461.38k | 2.26% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 413.22k | 2.02% |
| Castleknight Management LPas of 30 Sep 2025 | 399.78k | 1.96% |
| Dana Investment Advisors, Inc.as of 31 Dec 2025 | 328.68k | 1.61% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
